Back to Journals » ClinicoEconomics and Outcomes Research » Volume 4

Costs and clinical consequences of suboptimal atrial fibrillation management

Authors Singh S

Received 21 January 2012

Accepted for publication 20 February 2012

Published 26 March 2012 Volume 2012:4 Pages 79—90


Review by Single anonymous peer review

Peer reviewer comments 3

Steven N Singh

Department of Cardiology, Veterans Affairs Medical Center, Washington, DC, USA

Abstract: Atrial fibrillation (AF) places a considerable burden on the US health care system, society, and individual patients due to its associated morbidity, mortality, and reduced health-related quality of life. AF increases the risk of stroke, which often results in lengthy hospital stays, increased disability, and long-term care, all of which impact medical costs. An expected increase in the prevalence of AF and incidence of AF-related stroke underscores the need for optimal management of this disorder. Although AF treatment strategies have been proven effective in clinical trials, data show that patients still receive suboptimal treatment. Adherence to AF treatment guidelines will help to optimize treatment and reduce costs due to AF-associated events; new treatments for AF show promise for future reductions in disease and cost burden due to improved tolerability profiles. Additional research is necessary to compare treatment costs and outcomes of new versus existing agents; an immediate effort to optimize treatment based on existing evidence and guidelines is critical to reducing the burden of AF.

Keywords: atrial fibrillation, pharmacoeconomics, stroke, health-related quality of life

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.